News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–9
Matches
9
Sources here
8
Companies here
1
Search results Stored financial headlines

Active search

9 matching headlines

Ticker or company: M1RN34Main company stories
Clear
Latest

finance.yahoo.com Earnings

Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?

Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings? What a fantastic six months it's been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation. Is now the time to buy Moderna, or should you …

Main company 🇧🇷 Brazil
Read at finance.yahoo.com
Sharemaestro market context Trend signal active 52 weeks +119.9% M1RN34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with …

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +119.9% M1RN34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

nasdaq.com Earnings Main company 🇧🇷 Brazil

Moderna (MRNA) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Stphane BancelPresident - Stephen HogeChief Financial Officer - James MockChief Development Officer - David Berman TAKEAWAYS Total Revenue -- $145 million, representing 2% growth …

M1RN34 main company
Sharemaestro market context Trend signal active 52 weeks +119.9% M1RN34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context